Background. Surgical treatment of sacral chordoma remains one of the most challenging areas of medicine. Despite advances in oncology, en-bloc resection continues to represent the gold standard of treatment. The absence of relevant cohort studies in the domestic literature prompted us to systematize and present our own experience. The aim of the study - to analyze the short-term and long-term outcomes of surgical treatment of sacral chordomas using en-bloc resection. Methods. A monocentric cohort study evaluated results of en-bloc sacral resection in 9 patients with histologically verified sacral chordomas. Follow-up period was evaluated 2 yrs 4 mos( +/-) 5 mos. Comprehensive analysis included surgical technique, health-related quality of life, post-op complication rates, recurrence-free survival, and local tumor control. Diagnostic and therapeutic delay duration, intraoperative blood loss, and operative time were assessed. Results. Follow-up duration: 2 yrs 4 mos +/- 5 mos [1 yr 2 mos; 4 yrs 10 mos]. No significant differences identified between diagnostic and therapeutic delay durations. Intraoperative blood loss: 422 +/- 220 ml; operative duration: 3 hrs 11 mins +/- 67 mins. All patients demonstrated significant reduction in low-back pain postoperatively (p = 0.003). Similar improvement trends in health-related quality of life according to Oswestry Disability Index (ODI) (p = 0.007) and SF-12 questionnaire (p = 0.003). Preoperative neurological deficit occurred in 33% of patients (Frankel D lower paraparesis); pelvic organ dysfunction noted in 77%. Postoperative complications (Clavien-Dindo III b) occurred in 4 cases. R0 resection margins confirmed in all cases. Overall and recurrence-free survival: 100%. Conclusion. This cohort study demonstrates the efficacy and safety of en-bloc sacral chordoma resection. The procedure achieves 100% resectability, high local control rates, and improved postoperative quality of life.